{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:47:10Z","timestamp":1789195630625,"version":"build-2803163510"},"reference-count":35,"publisher":"Portland Press Ltd.","issue":"9","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:p>Clinical studies have shown that patients with early Type\u00a02 diabetes often have elevated serum glucagon rather than insulin deficiency. Imbalance of insulin and glucagon in favouring the latter may contribute to impaired glucose tolerance, persistent hyperglycaemia, microalbuminuria and glomerular injury. In the present study, we tested the hypothesis that long-term glucagon infusion induces early metabolic and renal phenotypes of Type\u00a02 diabetes in mice by activating glucagon receptors. Five groups of adult male C57BL\/6J mice were treated with vehicle, glucagon alone (1\u00a0\u03bcg\/h via an osmotic minipump, intraperitoneally), glucagon plus the glucagon receptor antagonist [Des-His1-Glu9]glucagon (5\u00a0\u03bcg\/h via an osmotic minipump), [Des-His1-Glu9]glucagon alone or a high glucose load alone (2% glucose in the drinking water) for 4\u00a0weeks. Glucagon infusion increased serum glucagon by 129% (P&amp;lt;0.05), raised systolic BP (blood pressure) by 21\u00a0mmHg (P&amp;lt;0.01), elevated fasting blood glucose by 42% (P&amp;lt;0.01), impaired glucose tolerance (P&amp;lt;0.01), increased the kidney weight\/body weight ratio (P&amp;lt;0.05) and 24\u00a0h urinary albumin excretion by 108% (P&amp;lt;0.01) and induced glomerular mesangial expansion and extracellular matrix deposition. These responses were associated with marked increases in phosphorylated ERK1\/2 (extracellular-signal-regulated kinase 1\/2) and Akt signalling proteins in the liver and kidney (P&amp;lt;0.01). Serum insulin did not increase proportionally. Concurrent administration of [Des-His1-Glu9]glucagon with glucagon significantly attenuated glucagon-increased BP, fasting blood glucose, kidney weight\/body weight ratio and 24\u00a0h urinary albumin excretion. [Des-His1-Glu9]glucagon also improved glucagon-inpaired glucose tolerance, increased serum insulin by 56% (P&amp;lt;0.05) and attenuated glomerular injury. However, [Des-His1-Glu9]glucagon or high glucose administration alone did not elevate fasting blood glucose levels, impair glucose tolerance or induce renal injury. These results demonstrate for the first time that long-term hyperglucagonaemia in mice induces early metabolic and renal phenotypes of Type\u00a02 diabetes by activating glucagon receptors. This supports the idea that glucagon receptor blockade may be beneficial in treating insulin resistance and Type\u00a02 diabetic renal complications.<\/jats:p>","DOI":"10.1042\/cs20070257","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T14:49:24Z","timestamp":1207147764000},"page":"591-601","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type\u00a02 diabetes in mice"],"prefix":"10.1042","volume":"114","author":[{"given":"Xiao\u00a0C.","family":"Li","sequence":"first","affiliation":[{"name":"Laboratory of Receptor and Signal Transduction, Division of Hypertension and Vascular Research, Henry Ford Hospital, Detroit, MI 48202, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang-dong","family":"Liao","sequence":"additional","affiliation":[{"name":"Laboratory of Receptor and Signal Transduction, Division of Hypertension and Vascular Research, Henry Ford Hospital, Detroit, MI 48202, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia\u00a0L.","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Laboratory of Receptor and Signal Transduction, Division of Hypertension and Vascular Research, Henry Ford Hospital, Detroit, MI 48202, U.S.A."},{"name":"Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48202, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2008,4,2]]},"reference":[{"key":"2021120120503585900_B1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"International Union of Pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"2021120120503585900_B2","doi-asserted-by":"crossref","first-page":"E671","DOI":"10.1152\/ajpendo.00492.2002","article-title":"Glucagon and regulation of glucose metabolism","volume":"284","author":"Jiang","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021120120503585900_B3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2006-0007","article-title":"Alpha-cells of the endocrine pancreas: 35\u00a0years of research but the enigma remains","volume":"28","author":"Gromada","year":"2007","journal-title":"Endocr. Rev."},{"key":"2021120120503585900_B4","first-page":"585","article-title":"Pathophysiology and pharmacological treatment of insulin resistance","volume":"21","author":"Matthaei","year":"2000","journal-title":"Endocr. Rev."},{"key":"2021120120503585900_B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1681\/ASN.2004080648","article-title":"Mouse models of diabetic nephropathy","volume":"16","author":"Breyer","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021120120503585900_B6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI112846","article-title":"Hyperglucagonemia and insulin-mediated glucose metabolism","volume":"79","author":"Prato","year":"1987","journal-title":"J. Clin. Invest."},{"key":"2021120120503585900_B7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(75)92375-2","article-title":"The essential role of glucagon in the pathogenesis of diabetes mellitus","volume":"i","author":"Unger","year":"1975","journal-title":"Lancet"},{"key":"2021120120503585900_B8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/jcem-64-1-106","article-title":"Documentation of hyperglucagonemia through the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus","volume":"64","author":"Reaven","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120503585900_B9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI115012","article-title":"Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine","volume":"87","author":"Orskov","year":"1991","journal-title":"J. Clin. Invest."},{"key":"2021120120503585900_B10","first-page":"4053","article-title":"Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type\u00a02 diabetes mellitus","volume":"85","author":"Shah","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120503585900_B11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0026-0495(83)90206-8","article-title":"Chronic hyperglucagonemia in rats: effects on insulin, substrates, and hepatic enzymes of intermediary metabolism","volume":"32","author":"Gruppuso","year":"1983","journal-title":"Metab. Clin. Exp."},{"key":"2021120120503585900_B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0005-2760(88)90283-4","article-title":"Effects of chronic glucagon administration on cholesterol and bile acid metabolism","volume":"963","author":"Guettet","year":"1988","journal-title":"Biochim. Biophys. Acta"},{"key":"2021120120503585900_B13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00421-002-0766-2","article-title":"Effects of inducing physiological hyperglucagonemia on metabolic responses to exercise","volume":"89","author":"Belanger","year":"2004","journal-title":"Eur. J. Appl. Physiol."},{"key":"2021120120503585900_B14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2337\/diabetes.53.2.410","article-title":"Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db\/db mice","volume":"53","author":"Liang","year":"2004","journal-title":"Diabetes"},{"key":"2021120120503585900_B15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI20911","article-title":"Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors","volume":"113","author":"Sloop","year":"2004","journal-title":"J. Clin. Invest."},{"key":"2021120120503585900_B16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/323068a0","article-title":"Activation of two signal-transduction systems in hepatocytes by glucagon","volume":"323","author":"Wakelam","year":"1986","journal-title":"Nature"},{"key":"2021120120503585900_B17","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1126\/science.8384375","article-title":"Expression cloning and signaling properties of the rat glucagon receptor","volume":"259","author":"Jelinek","year":"1993","journal-title":"Science"},{"key":"2021120120503585900_B18","first-page":"F656","article-title":"Postprandial regulation of renal hemodynamics: role of pancreatic glucagon","volume":"248","author":"Premen","year":"1985","journal-title":"Am. J. Physiol."},{"key":"2021120120503585900_B19","first-page":"F225","article-title":"Influence of glucagon on GFR and on urea and electrolyte excretion: direct and indirect effects","volume":"38","author":"Ahloulay","year":"1995","journal-title":"Am. J. Physiol."},{"key":"2021120120503585900_B20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1113\/jphysiol.1988.sp017192","article-title":"Effects of atrial natriuretic peptide and glucagon on proximal glomerulotubular balance in anesthetized rats","volume":"402","author":"Harris","year":"1988","journal-title":"J. Physiol."},{"key":"2021120120503585900_B21","first-page":"941","article-title":"Mechanisms of glucagon-induced renal vasodilation: role of prostaglandins and endothelium-derived relaxing factor","volume":"120","author":"Tolins","year":"2004","journal-title":"J. Lab. Clin. Med."},{"key":"2021120120503585900_B21a","first-page":"e75","article-title":"Long-term hyperglucagonemia induces early Type\u00a02 diabetic phenotypes in mice: role of glucagon receptors and angiotensin II","volume":"48","author":"Li","year":"2007","journal-title":"Hypertension"},{"key":"2021120120503585900_B22","doi-asserted-by":"crossref","first-page":"F586","DOI":"10.1152\/ajprenal.00489.2006","article-title":"Genetic deletion of AT1a receptors attenuates intracellular accumulation of Val5-angiotensin II in the kidney of AT1a receptor-deficient mice","volume":"293","author":"Li","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021120120503585900_B23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/hy0102.100780","article-title":"Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: Role of AT1 receptor","volume":"39","author":"Zhuo","year":"2002","journal-title":"Hypertension"},{"key":"2021120120503585900_B24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2337\/diabetes.51.2.398","article-title":"Glucagon replacement via microosmotic minipump corrects hypoglycemia and \u03b1-cell hyperplasia in prohormone convertase 2 knockout mice","volume":"51","author":"Webb","year":"2002","journal-title":"Diabetes"},{"key":"2021120120503585900_B25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s001250100006","article-title":"Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans","volume":"44","author":"Petersen","year":"2001","journal-title":"Diabetologia"},{"key":"2021120120503585900_B26","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/0196-9781(89)90010-7","article-title":"Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist","volume":"10","author":"Unson","year":"1989","journal-title":"Peptides"},{"key":"2021120120503585900_B27","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1073\/pnas.0237106100","article-title":"Lower blood glucose, hyperglucagonemia, and pancreatic \u03b1 cell hyperplasia in glucagon receptor knockout mice","volume":"100","author":"Gelling","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021120120503585900_B28","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1210\/en.2005-1410","article-title":"Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation","volume":"147","author":"Vuguin","year":"2006","journal-title":"Endocrinology"},{"key":"2021120120503585900_B29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.HYP.0000197946.81754.0a","article-title":"Glucagon receptor-mediated ERK 1\/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C","volume":"47","author":"Li","year":"2006","journal-title":"Hypertension"},{"key":"2021120120503585900_B30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bcp.2006.03.018","article-title":"Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1\/2 in rat glomerular mesangial cells","volume":"71","author":"Li","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"2021120120503585900_B31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1042\/CS20070040","article-title":"Targeting glucagon receptor signaling in treating metabolic syndrome and renal injury in Type\u00a02 diabetes: theory versus promise","volume":"113","author":"Li","year":"2007","journal-title":"Clin. Sci."},{"key":"2021120120503585900_B32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/snep.2003.50017","article-title":"Hyperfiltration and glomerulosclerosis","volume":"23","author":"Hostetter","year":"2003","journal-title":"Semin. Nephrol."},{"key":"2021120120503585900_B33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021120120503585900_B34","doi-asserted-by":"crossref","first-page":"10102","DOI":"10.1073\/pnas.131200398","article-title":"Glucagon receptor activates extracellular signal-regulated protein kinase 1\/2 via cAMP-dependent protein kinase","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/114\/9\/591\/438795\/cs1140591.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/114\/9\/591\/438795\/cs1140591.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T21:50:16Z","timestamp":1638395416000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/114\/9\/591\/68436\/Long-term-hyperglucagonaemia-induces-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,2]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20070257","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,2]]}}}